BC Cancer Protocol Summary for Therapy of Lymphoma, Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma Using Cyclophosphamide

Protocol Code

LYCYCLO

Tumour Group

Lymphoma

Contact Physician

Dr. Laurie Sehn

ELIGIBILITY:

- Malignant lymphoma, Hodgkin’s lymphoma, chronic lymphocytic leukemia, multiple myeloma

EXCLUSIONS:

- Active hemolytic anemia or immune-related thrombocytopenia

TESTS:

- Baseline (required before first treatment): CBC and diff, platelets, bilirubin, ALT
- Baseline (required, but results do not have to be available to proceed with first treatment; results must be checked before proceeding with cycle 2): HBsAg, HBcoreAb
- Before each treatment: CBC and diff, platelets

PREMEDICATIONS:

ondansetron 8 mg PO/IV daily pre chemo
dexamethasone 12 mg PO/IV daily pre chemo

SUPPORTIVE MEDICATIONS:

If HBsAg or HBcoreAb positive, start lamivudine 100 mg/day PO for the duration of chemotherapy and for six months afterwards.

TREATMENT:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>BC Cancer Administration Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>cyclophosphamide</td>
<td>600-1200 mg/m²* on day 1</td>
<td>IV in 100 to 250** mL NS over 20 min to 1 h</td>
</tr>
<tr>
<td>OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>cyclophosphamide</td>
<td>300-400 mg/m²/day* x 5 days***</td>
<td>PO</td>
</tr>
<tr>
<td>PLUS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>prednisone (optional)</td>
<td>45 mg/m² daily x 5 days***</td>
<td>PO in am with food</td>
</tr>
</tbody>
</table>

*The actual dose depends on patient specific factors such as extent of prior treatment, performance status, duration of planned treatment and others.

**Use 250 mL for dose greater than or equal to 1000 mg

***Round to the nearest 25 mg; if Cyclophosphamide is being given daily and dexamethasone is being used as an anti-emetic prednisone should be omitted
Repeat every 21-28 days. Discontinue if no response after 2 cycles. Continue treatment until 2 cycles after maximum response, to a maximum of 8 months of treatment.

Activated: 1 Jan 1980 Revised: 1 Apr 2020 (AST removed, institutional name updated)

Warning: The information contained in these documents is a statement of consensus of BC Cancer professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these documents is at your own risk and is subject to BC Cancer’s terms of use available at www.bccancer.bc.ca/terms-of-use
DOSE MODIFICATIONS:

1. **Hematological, for low counts due to treatment**

<table>
<thead>
<tr>
<th>ANC (x10⁹/L)</th>
<th>Platelets (x10⁹/L)</th>
<th>Dose (all drugs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>greater than 1.2</td>
<td>greater than 80</td>
<td>100%</td>
</tr>
<tr>
<td>less than or equal to 1.2</td>
<td>less than or equal to 80</td>
<td>Delay until recovery</td>
</tr>
</tbody>
</table>

2. **Renal dysfunction**: Dose modification may be required for cyclophosphamide. Refer to BC Cancer Drug Manual.

PRECAUTIONS:

1. **Neutropenia**: Fever or other evidence of infection must be assessed promptly and treated aggressively.

2. **Hepatitis B Reactivation**: All lymphoma patients should be tested for both HBsAg and HBcAb. If either test is positive, such patients should be treated with lamivudine during chemotherapy and for six months afterwards. Such patients should also be monitored with frequent liver function tests and hepatitis B virus DNA at least every two months. If the hepatitis B virus DNA level rises during this monitoring, management should be reviewed with an appropriate specialist with experience managing hepatitis and consideration given to halting chemotherapy.

Call Dr. Laurie Sehn or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.